To study the role of kinase deregulation in tumor initiation and/or progression, Robinson-Garcia et al. developed a CRISPR-Cas9 systematic approach to identify synthetic lethal interactions for kinase deficiencies to different DNA-damaging chemotherapeutic agents using HAP1 (Robinson-Garcia et al., 2019). The gene discussed is HAP1; the disease is neoplasm.